Opinion|Videos|October 16, 2024
Patient Education and Emerging Therapies
Panelists discuss how health care providers can improve patient education and support for type 2 inflammatory conditions through personalized communication strategies and shared decision-making, while also evaluating the role of emerging biologic therapies in treatment plans based on individual patient factors, disease severity, and biomarker profiles.
Advertisement
- How can health care providers better educate and support patients in understanding type 2 inflammatory conditions and adhering to treatment plans?
- What are your perspectives on the emerging biologic therapies targeting type 2 inflammation? How do you determine when these treatments may be appropriate for your patients?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- BCMA-Targeted Bispecific Antibodies: Navigating the New Frontier of Myeloma
September 17th 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
2
Cumulative Atropine Not Associated With Increased Risk of Ocular Events in Children With Myopia
3
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5